A novel vaccine against cancer-causing human papillomaviruses (HPV) is intended to help raise vaccination rates especially in developing countries. To this end, scientists from the German Cancer Research Center (DKFZ) in Heidelberg are developing a completely new vaccination concept based on a low-cost vaccine that protects from almost all known oncogenic HPV types. The project has now been…
A new EC-funded project will bring together medical and radiation scientists, physicists and clinicians to enhance the radiation protection of patients and medical professionals. The four-year MEDIRAD project, which kicked off in June 2017, is led by the European Institute for Biomedical Imaging Research – EIBIR (AT) and comprises a consortium of 33 partners from 14 European countries.
Many tumors possess mechanisms to avoid destruction by the immune system. For instance, they misuse the natural “brakes” in the immune defense mechanism, which normally prevent an excessive immune response. Researchers at the University of Bonn have now been able to take off one of these brakes. The study, which involved colleagues from Hamburg and Würzburg, could pave the way for more…
Columbia University Medical Center (CUMC) researchers have identified cells in the upper digestive tract that can give rise to Barrett’s esophagus, a precursor to esophageal cancer. The discovery of this “cell of origin” promises to accelerate the development of more precise screening tools and therapies for Barrett’s esophagus and esophageal adenocarcinoma, the fastest growing form of…
A group of international cancer researchers led by investigators from Mayo Clinic and University of New South Wales Sydney has found that the level of a type of white blood cell, called tumor-infiltrating lymphocytes, present in the tumors of patients with high-grade ovarian cancer may predict a patient’s survival. “We know that a type of tumor-infiltrating lymphocyte called cytotoxic CD8 are…
Surgeons at Penn Medicine are using a fluorescent dye that makes cancerous cells glow in hopes of identifying suspicious lymph nodes during head and neck cancer procedures. Because the tumors glow, surgeons get real-time guidance to help them take out as much cancer as possible and leave non-diseased tissue alone.
The majority of cancer drugs approved in Europe between 2009 and 2013 entered the market without clear evidence that they improved survival or quality of life for patients, finds a study published by The BMJ. Even where drugs did show survival gains over existing treatments, these were often marginal, the results show. Many of the drugs were approved on the basis of indirect (‘surrogate’)…
It had already been known that the enzyme known as phosphatidic acid phosphatase plays a crucial role in regulating the amount of fat in the human body. Controlling it is therefore of interest in the fight against obesity. But scientists at Rutgers University-New Brunswick have now found that getting rid of the enzyme entirely can increase the risk of cancer, inflammation and other ills.
A team of scientists and engineers at The University of Texas at Austin has invented a powerful tool that rapidly and accurately identifies cancerous tissue during surgery, delivering results in about 10 seconds—more than 150 times as fast as existing technology.
As cancer grows, it evolves. Individual cells become more aggressive and break away to flow through the body and spread to distant areas. What if there were a way to find those early aggressors? How are they different from the rest of the cells? And more importantly: Is there a way to stop them before they spread?
Recent outbreaks of Zika virus have revealed that the virus causes brain defects in unborn children. But researchers from Washington University School of Medicine in St. Louis and the University of California, San Diego report that the virus could eventually be used to target and kill cancer cells in the brain.
Neagen and Visiopharm announce an integration which improves the data quality of cancer patient samples in a single PACS-driven digital pathology workflow also offering time and cost savings. This in term enhances quality for pathologists working in cancer research and diagnostics and benefits the patients.
Every cancer is different and every patient is different. This insight gained in personalised medicine prompted oncology researchers to focus more on the individual patient’s immune system. It is particularly the immune system’s ability to destroy cancer cells that raised hope.
A nanolaser known as the spaser can serve as a super-bright, water-soluble, biocompatible probe capable of finding metastasized cancer cells in the blood stream and then killing these cells, according to a new research study.
“When you’re told you have cancer, it’s not a light thing.” And when that diagnosis comes, patients and medical staff alike want to be able to focus on one thing: care that leads to the best outcome.
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood.
Headlines, of late, have touted the successes of targeted gene-based cancer therapies, such as immunotherapies, but, unfortunately, also their failures.
Scientists from the University of Würzburg have synthesized a complex sugar molecule which specifically binds to the tumor protein Galectin-1. This could help to recognize tumors at an early stage and to combat them in a targeted manner.
Unlike the USA, Italy, Germany or the Netherlands, Spain does not include hyperthermia in its national health catalogue. Worse, many non-medical centres are increasingly offering hyperthermia as an alternative treatment, a situation that infuriates Spanish oncologic radiotherapists.
Findings suggest that modifying the cell replication cycle could make combined therapies more successful.
A pioneering diagnostic device identifies more abnormal cells on the cervix than standard colposcopy, according to data published in two European clinical papers.
Pancreatic cancer is one of the most deadly types of malignancies, with a 5-year survival rate after late diagnosis of only about 5%. The majority of patients—about 80%—receive their diagnosis too late for surgery. The disease spreads quickly and resists chemotherapy. In short, there is an urgent need for diagnostic tools to identify this cancer in its earliest stages.
The UC Davis Comparative Oncology Program joins oncologists at both the vet school and cancer center to test novel treatments on companion dogs with spontaneous tumors that could be effective in human patients with cancer. Human clinical trials could be started this year.
The U.S. Food and Drug Administration has cleared the expanded use of a cooling cap, DigniCap Cooling System, to reduce hair loss (alopecia) during chemotherapy. This is the first cooling cap cleared by the agency for use in cancer patients with solid tumors.
Canadian researchers have invented an intraoperative probe that reliably detects multiple types of tumour cells.
